Effect of FOXP2 transcription factor on immune infiltration of thyroid cancer and its potential clinical value

Background The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of FOXP2 in tumor invasion and recurrence was investigated consequently. Me...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 982812
Main Authors Xu, Lianghui, Yang, Zheyu, Zhao, Qiwu, Feng, Haoran, Kuang, Jie, Liu, Zhuoran, Chen, Linxie, Zhan, Lin, Yan, Jiqi, Cai, Wei, Qiu, Weihua
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 20.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of FOXP2 in tumor invasion and recurrence was investigated consequently. Methods TIMER and GEPIA were firstly employed to compare FOXPs expression in normal and cancer tissues from multiple human cancers. The results from database were confirmed by quantitative Real Time-PCR and Western blot in matched thyroid cancer and adjacent normal tissues, in addition to a panel of thyroid cancer cell lines and normal thyroid cell. GEPIA platform was employed to discover the possibility of FOXPs as prognostic indicator. TISIBD and UACLCAN were then employed to estimate the influence of FOXPs on lymph node metastasis and tumor staging. GEPIA analysis was initially employed to analyze correlation of FOXPs and tumor immune infiltrating cells, and TIMER dataset was then included for standardization according to tumor purity. Result Different member of FOXPs showed divergence in expression in various cancer tissues. Lower FOXP1, FOXP2 and higher FOXP3, FOXP4 levels could be identified in thyroid cancer tissues when compared with matched normal tissue. There was an inverse correlation between FOXP2, FOXP4 and immune invasion, whereas FOXP1 and FOXP3 were positively correlated. FOXPs showed remarkable correlations with multiply immune cells. More importantly, only FOXP2 showed the significant effect on recurrence and tumor staging. Conclusion As immune regulatory factor, the reduction of FOXP2 may affect tumor microenvironments and immune cells infiltration, enhance tumor immune escape, and promote recurrence of thyroid cancer. FOXP2 could be a new potential diagnostic and prognostic marker.
AbstractList Background The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of FOXP2 in tumor invasion and recurrence was investigated consequently. Methods TIMER and GEPIA were firstly employed to compare FOXPs expression in normal and cancer tissues from multiple human cancers. The results from database were confirmed by quantitative Real Time-PCR and Western blot in matched thyroid cancer and adjacent normal tissues, in addition to a panel of thyroid cancer cell lines and normal thyroid cell. GEPIA platform was employed to discover the possibility of FOXPs as prognostic indicator. TISIBD and UACLCAN were then employed to estimate the influence of FOXPs on lymph node metastasis and tumor staging. GEPIA analysis was initially employed to analyze correlation of FOXPs and tumor immune infiltrating cells, and TIMER dataset was then included for standardization according to tumor purity. Result Different member of FOXPs showed divergence in expression in various cancer tissues. Lower FOXP1, FOXP2 and higher FOXP3, FOXP4 levels could be identified in thyroid cancer tissues when compared with matched normal tissue. There was an inverse correlation between FOXP2, FOXP4 and immune invasion, whereas FOXP1 and FOXP3 were positively correlated. FOXPs showed remarkable correlations with multiply immune cells. More importantly, only FOXP2 showed the significant effect on recurrence and tumor staging. Conclusion As immune regulatory factor, the reduction of FOXP2 may affect tumor microenvironments and immune cells infiltration, enhance tumor immune escape, and promote recurrence of thyroid cancer. FOXP2 could be a new potential diagnostic and prognostic marker.
BackgroundThe clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of FOXP2 in tumor invasion and recurrence was investigated consequently.MethodsTIMER and GEPIA were firstly employed to compare FOXPs expression in normal and cancer tissues from multiple human cancers. The results from database were confirmed by quantitative Real Time-PCR and Western blot in matched thyroid cancer and adjacent normal tissues, in addition to a panel of thyroid cancer cell lines and normal thyroid cell. GEPIA platform was employed to discover the possibility of FOXPs as prognostic indicator. TISIBD and UACLCAN were then employed to estimate the influence of FOXPs on lymph node metastasis and tumor staging. GEPIA analysis was initially employed to analyze correlation of FOXPs and tumor immune infiltrating cells, and TIMER dataset was then included for standardization according to tumor purity.ResultDifferent member of FOXPs showed divergence in expression in various cancer tissues. Lower FOXP1, FOXP2 and higher FOXP3, FOXP4 levels could be identified in thyroid cancer tissues when compared with matched normal tissue. There was an inverse correlation between FOXP2, FOXP4 and immune invasion, whereas FOXP1 and FOXP3 were positively correlated. FOXPs showed remarkable correlations with multiply immune cells. More importantly, only FOXP2 showed the significant effect on recurrence and tumor staging.ConclusionAs immune regulatory factor, the reduction of FOXP2 may affect tumor microenvironments and immune cells infiltration, enhance tumor immune escape, and promote recurrence of thyroid cancer. FOXP2 could be a new potential diagnostic and prognostic marker.
Author Xu, Lianghui
Zhan, Lin
Yan, Jiqi
Zhao, Qiwu
Yang, Zheyu
Liu, Zhuoran
Chen, Linxie
Kuang, Jie
Feng, Haoran
Qiu, Weihua
Cai, Wei
AuthorAffiliation Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China
AuthorAffiliation_xml – name: Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China
Author_xml – sequence: 1
  givenname: Lianghui
  surname: Xu
  fullname: Xu, Lianghui
– sequence: 2
  givenname: Zheyu
  surname: Yang
  fullname: Yang, Zheyu
– sequence: 3
  givenname: Qiwu
  surname: Zhao
  fullname: Zhao, Qiwu
– sequence: 4
  givenname: Haoran
  surname: Feng
  fullname: Feng, Haoran
– sequence: 5
  givenname: Jie
  surname: Kuang
  fullname: Kuang, Jie
– sequence: 6
  givenname: Zhuoran
  surname: Liu
  fullname: Liu, Zhuoran
– sequence: 7
  givenname: Linxie
  surname: Chen
  fullname: Chen, Linxie
– sequence: 8
  givenname: Lin
  surname: Zhan
  fullname: Zhan, Lin
– sequence: 9
  givenname: Jiqi
  surname: Yan
  fullname: Yan, Jiqi
– sequence: 10
  givenname: Wei
  surname: Cai
  fullname: Cai, Wei
– sequence: 11
  givenname: Weihua
  surname: Qiu
  fullname: Qiu, Weihua
BookMark eNpVkc1qHDEQhIfgQBzHD5CbjrnsZtSaH-kSCMZODAb74EBuokdq2TIz0kbSGPz20e6aEOuiorv0dYv62JyEGKhpPvN2K4RUX51flnULLcBWSZAc3jWnfBi6jQDoTv7TH5rznJ_aejolhOhPm3DpHJnComNXt7_vgJWEIZvkd8XHwByaEhOraj8iEPPB-bl6Dt36qDy-pOgtMxgMJYbBMl8y28VCoXicmZl98KaKZ5xX-tS8dzhnOn-9z5pfV5f3Fz83N7c_ri--32xM10HZTDgY7qQiQ5MYoUXVYi-RJsUVqLp6i6ITk-StAotTb7vBiB6mAWhU1oA4a66PXBvxSe-SXzC96IheHwoxPWhMxZuZNIdxlFZOxKnrektywt7A4NyojBycraxvR9ZunRaypn4s4fwG-rYT_KN-iM9a9YLDICvgyysgxT8r5aIXnw3NMwaKa9YwguC95IOoVn60mhRzTuT-jeGt3metD1nrfdb6mLX4C8MJokY
CitedBy_id crossref_primary_10_3390_cancers15051468
Cites_doi 10.1080/23723556.2015.1019022
10.1093/intimm/dxac013
10.3389/fimmu.2021.613492
10.1172/JCI32538
10.1186/s40425-018-0378-y
10.1186/s12943-019-1110-3
10.1038/s41416-021-01340-x
10.1038/sj.leu.2403644
10.7759/cureus.4127
10.1007/s13277-015-3701-y
10.1016/j.pharmthera.2017.08.003
10.1038/nrg2523
10.3389/fendo.2020.570604
10.3390/ijms20184413
10.3390/vaccines4040041
10.1080/15384047.2018.1537999
10.1158/1078-0432.CCR-16-0484
10.1038/modpathol.2008.74
10.1186/s12885-019-5380-3
10.1136/jclinpath-2012-201335
10.1016/S2213-8587(21)00027-9
10.3892/etm.2022.11361
10.1210/jc.2011-3428
10.18632/aging.101918
10.3892/mmr.2014.2197
10.1242/dev.112672
10.1093/molbev/msq182
10.1111/cpr.12312
10.1210/jc.2009-2564
10.3390/ijms19103279.
10.1111/cen.13369
10.1089/thy.2018.0684
ContentType Journal Article
Copyright Copyright © 2022 Xu, Yang, Zhao, Feng, Kuang, Liu, Chen, Zhan, Yan, Cai and Qiu 2022 Xu, Yang, Zhao, Feng, Kuang, Liu, Chen, Zhan, Yan, Cai and Qiu
Copyright_xml – notice: Copyright © 2022 Xu, Yang, Zhao, Feng, Kuang, Liu, Chen, Zhan, Yan, Cai and Qiu 2022 Xu, Yang, Zhao, Feng, Kuang, Liu, Chen, Zhan, Yan, Cai and Qiu
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fimmu.2022.982812
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
EndPage 982812
ExternalDocumentID oai_doaj_org_article_12778d8be1e445de8ba5c26ff79c86fd
10_3389_fimmu_2022_982812
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
ITC
5PM
ID FETCH-LOGICAL-c442t-ba6c1f89eceb3720a90a58aeb919299330a343b81092dab5d46c352b62e79dc23
IEDL.DBID RPM
ISSN 1664-3224
IngestDate Fri Oct 04 13:14:31 EDT 2024
Tue Sep 17 21:30:33 EDT 2024
Fri Aug 16 21:27:43 EDT 2024
Thu Sep 26 16:11:52 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-ba6c1f89eceb3720a90a58aeb919299330a343b81092dab5d46c352b62e79dc23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors have contributed equally to this work
Edited by: Baochi Ou, First Affiliated Hospital of Anhui Medical University, China
Reviewed by: Leqi Zhou, Second Military Medical University, China; Luigi Cari, University of Perugia, Italy; Hang Zhou, Harbin Medical University, China
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531268/
PQID 2723158163
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_12778d8be1e445de8ba5c26ff79c86fd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9531268
proquest_miscellaneous_2723158163
crossref_primary_10_3389_fimmu_2022_982812
PublicationCentury 2000
PublicationDate 2022-09-20
PublicationDateYYYYMMDD 2022-09-20
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-20
  day: 20
PublicationDecade 2020
PublicationTitle Frontiers in immunology
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Miranda-Filho (B1) 2021; 9
Santos (B17) 2011; 28
French (B33) 2012; 97
Yan (B24) 2015; 36
Stumm (B29) 2013; 66
Yang (B16) 2022; 23
Bach (B18) 2018; 19
Streubel (B11) 2005; 19
Golson (B7) 2016; 143
Iyer (B5) 2018; 6
Xie (B30) 2020; 11
Li (B26) 2015; 20
Goatly (B10) 2008; 21
Cuiffo (B22) 2016; 3
Xue (B21) 2014; 10
Poggi (B23) 2016; 4
Raue (B3) 2016; 22
Liang (B14) 2021; 125
Mehnert (B4) 2019; 19
Cuiffo (B20) 2016; 3
Hannenhalli (B8) 2009; 10
Liu (B15) 2019; 11
Zuo (B25) 2007; 117
Ahn (B31) 2019; 29
Kim (B12) 2019; 18
Nagasaki (B35) 2022
Nixon (B13) 2017; 87
Li (B27) 2017; 50
Ferrari (B6) 2019; 20
Peng (B32) 2021; 12
Wang (B28) 2015; 8
Wang (B9) 2018; 181
Olson (B2) 2019; 11
Sheng (B19) 2019; 20
French (B34) 2010; 95
References_xml – volume: 3
  year: 2016
  ident: B22
  article-title: Silencing FOXP2 in breast cancer cells promotes cancer stem cell traits and metastasis
  publication-title: Mol Cell Oncol
  doi: 10.1080/23723556.2015.1019022
  contributor:
    fullname: Cuiffo
– start-page: dxac013
  year: 2022
  ident: B35
  article-title: A variety of ‘exhausted’ T cells in the tumor microenvironment
  publication-title: Int Immunol
  doi: 10.1093/intimm/dxac013
  contributor:
    fullname: Nagasaki
– volume: 12
  year: 2021
  ident: B32
  article-title: Metabolism of dendritic cells in tumor microenvironment: For immunotherapy
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.613492
  contributor:
    fullname: Peng
– volume: 117
  year: 2007
  ident: B25
  article-title: FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2
  publication-title: J Clin Invest
  doi: 10.1172/JCI32538
  contributor:
    fullname: Zuo
– volume: 6
  start-page: 68
  year: 2018
  ident: B5
  article-title: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-018-0378-y
  contributor:
    fullname: Iyer
– volume: 18
  start-page: 180
  year: 2019
  ident: B12
  article-title: Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1110-3
  contributor:
    fullname: Kim
– volume: 125
  start-page: 390
  year: 2021
  ident: B14
  article-title: The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis
  publication-title: Br J Cancer
  doi: 10.1038/s41416-021-01340-x
  contributor:
    fullname: Liang
– volume: 19
  year: 2005
  ident: B11
  article-title: T(3;4)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403644
  contributor:
    fullname: Streubel
– volume: 11
  year: 2019
  ident: B2
  article-title: Epidemiology of thyroid cancer: A review of the national cancer database, 2000-2013
  publication-title: Cureus
  doi: 10.7759/cureus.4127
  contributor:
    fullname: Olson
– volume: 36
  year: 2015
  ident: B24
  article-title: Downregulation of FOXP2 promoter human hepatocellular carcinoma cell invasion
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-3701-y
  contributor:
    fullname: Yan
– volume: 181
  year: 2018
  ident: B9
  article-title: Members of FOX family could be drug targets of cancers
  publication-title: Pharmacol Therapeut
  doi: 10.1016/j.pharmthera.2017.08.003
  contributor:
    fullname: Wang
– volume: 10
  year: 2009
  ident: B8
  article-title: The evolution of fox genes and their role in development and disease
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg2523
  contributor:
    fullname: Hannenhalli
– volume: 11
  year: 2020
  ident: B30
  article-title: Immune cell confrontation in the papillary thyroid carcinoma microenvironment
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2020.570604
  contributor:
    fullname: Xie
– volume: 20
  start-page: 4413
  year: 2019
  ident: B6
  article-title: Immune and inflammatory cells in thyroid cancer microenvironment
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20184413
  contributor:
    fullname: Ferrari
– volume: 4
  start-page: 41
  year: 2016
  ident: B23
  article-title: Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment
  publication-title: Vaccines-Basel
  doi: 10.3390/vaccines4040041
  contributor:
    fullname: Poggi
– volume: 20
  year: 2019
  ident: B19
  article-title: Knockdown of FOXP1 promotes the development of lung adenocarcinoma
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2018.1537999
  contributor:
    fullname: Sheng
– volume: 20
  year: 2015
  ident: B26
  article-title: Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in northern Chinese men
  publication-title: J BUON
  contributor:
    fullname: Li
– volume: 8
  year: 2015
  ident: B28
  article-title: MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4)
  publication-title: Int J Clin Exp Pathol
  contributor:
    fullname: Wang
– volume: 22
  year: 2016
  ident: B3
  article-title: Thyroid cancer: Risk-stratified management and individualized therapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-0484
  contributor:
    fullname: Raue
– volume: 21
  year: 2008
  ident: B10
  article-title: FOXP1 abnormalities in lymphoma: Translocation breakpoint mapping reveals insights into deregulated transcriptional control
  publication-title: Modern Pathol
  doi: 10.1038/modpathol.2008.74
  contributor:
    fullname: Goatly
– volume: 19
  start-page: 196
  year: 2019
  ident: B4
  article-title: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5380-3
  contributor:
    fullname: Mehnert
– volume: 66
  year: 2013
  ident: B29
  article-title: Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers
  publication-title: J Clin Pathol
  doi: 10.1136/jclinpath-2012-201335
  contributor:
    fullname: Stumm
– volume: 9
  year: 2021
  ident: B1
  article-title: Thyroid cancer incidence trends by histology in 25 countries: A population-based study
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(21)00027-9
  contributor:
    fullname: Miranda-Filho
– volume: 23
  start-page: 434
  year: 2022
  ident: B16
  article-title: FOXP2 regulates thyroid cancer cell proliferation and apoptosis via transcriptional activation of RPS6KA6
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2022.11361
  contributor:
    fullname: Yang
– volume: 97
  year: 2012
  ident: B33
  article-title: Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer
  publication-title: J Clin Endocr Metab
  doi: 10.1210/jc.2011-3428
  contributor:
    fullname: French
– volume: 3
  year: 2016
  ident: B20
  article-title: Silencing FOXP2 in breast cancer cells promotes cancer stem cell traits and metastasis
  publication-title: Mol Cell Oncol
  doi: 10.1080/23723556.2015.1019022
  contributor:
    fullname: Cuiffo
– volume: 11
  year: 2019
  ident: B15
  article-title: Epigenetic control of Foxp3 in intratumoral T-cells regulates growth of hepatocellular carcinoma
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.101918
  contributor:
    fullname: Liu
– volume: 10
  year: 2014
  ident: B21
  article-title: FOXP1 has a low expression in human gliomas and its overexpression inhibits proliferation, invasion and migration of human glioma U251 cells
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2014.2197
  contributor:
    fullname: Xue
– volume: 143
  year: 2016
  ident: B7
  article-title: Fox transcription factors: From development to disease
  publication-title: Development
  doi: 10.1242/dev.112672
  contributor:
    fullname: Golson
– volume: 28
  year: 2011
  ident: B17
  article-title: Alternative splicing and gene duplication in the evolution of the FoxP gene subfamily
  publication-title: Mol Biol Evol
  doi: 10.1093/molbev/msq182
  contributor:
    fullname: Santos
– volume: 50
  year: 2017
  ident: B27
  article-title: Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer
  publication-title: Cell Proliferat
  doi: 10.1111/cpr.12312
  contributor:
    fullname: Li
– volume: 95
  year: 2010
  ident: B34
  article-title: Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer
  publication-title: J Clin Endocr Metab
  doi: 10.1210/jc.2009-2564
  contributor:
    fullname: French
– volume: 19
  start-page: 3279
  year: 2018
  ident: B18
  article-title: The dominant role of forkhead box proteins in cancer
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms19103279.
  contributor:
    fullname: Bach
– volume: 87
  year: 2017
  ident: B13
  article-title: Circulating thyroid cancer biomarkers: Current limitations and future prospects
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/cen.13369
  contributor:
    fullname: Nixon
– volume: 29
  year: 2019
  ident: B31
  article-title: Low lymphocyte-to-Monocyte ratios are associated with poor overall survival in anaplastic thyroid carcinoma patients
  publication-title: Thyroid
  doi: 10.1089/thy.2018.0684
  contributor:
    fullname: Ahn
SSID ssj0000493335
Score 2.3805246
Snippet Background The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration...
BackgroundThe clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 982812
SubjectTerms clinical prognosis
diagnosis
FOXP2
immune infiltration
Immunology
thyroid cancer
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA4iCF7EJ64vIngS6rZp0iRHFRcRfBxc2FvIq1jRdlm7B_-9k2ZXticv3kqbknQmzXxfM_0GoQsA5bnl1idWpiyhlmSJAaCc5KXl3koOESoQxcen4n5MHyZsslLqK-SERXngaLhhRjgXThifeUqZ88JoZklRllxaUZSuW30ztkKm3iPuzfOcxW1MYGFyWFafn3Pgg4RcSWAZGekFok6vvwcy-ymSKzFntI22FmARX8dB7qA1X--ijVg-8nsP1VF6GDclHj1PXghuQ-BZLgM4ltLBcBQGVXsMk6n6WMjkhpvAR7OmctgGz8-wrh2u2i88bdqQQgQdL3-bxEES3O-j8eju9fY-WdRPSCylpE2MLmxWCuktMGZOUi1TzYT2RgKsk-FLhs5pbkSWSuK0YY4WFvCYKYjn0lmSH6D1uqn9IcKOcwvNqBbEAIGkmpbOMOq1B0AGIGqALpfGVNMok6GAXgTLq87yKlheRcsP0E0w92_DoHDdnQC_q4Xf1V9-H6DzpbMUvBFhm0PXvpl_KcIBszIBQHOAeM-LvR77V-rqrdPWlrAmkUIc_ccQj9FmeOqQXULSE7Tezub-FCBMa8662foDURHzHA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBYhpdBLaZuUbtsEFXIqOLFlWY9DCUnoEgppe-jC3oRebl0SO_V6ofn3nfEjxJBLb37IljUz0nyfJM8QcgSgPPfSx8TrtEi4Z1niACgneell9FqCh0KiePVVXK74l3Wx3iFTeqtRgJtHqR3mk1q118d__9ydQof_hIwT_O1JWd3cbIHqMXasgUBgzuEnjOccDf5qRPu_BzCc533KzUwInoAp82Gd8_G3zDxVH9B_hkLneygfOKXlC_J8RJP0bFD_S7IT61fk6ZBf8m6P1ENsYtqUdPlt_Z3RDj3TNE7QIdcOhSP8qDpSaH91PcbRxYdAiW1TBerRNFpq60CrbkNvmw73GEHF03-VFGOGx32yWn7-cXGZjAkWEs856xJnhc9KpaMHSi1ZanVqC2Wj04D7NE512JznTmWpZsG6InDhAbA5waLUwbP8Ndmtmzq-ITRI6aEYt4o5YJjc8jK4gkcbAbEBylqQj5Mwze0QR8MA_0DJm17yBiVvBskvyDmK-74ghsDuLzTtTzP2KJMxKVVQLmaR8yJE5WzhmShLqb0SZViQD5OyDHQZXAexdWy2G8MkgNpCARJdEDnT4qzG-Z26-tUH39YwaDGh3v5Pe96RZ3iG20xY-p7sdu02HgCW6dxhb6H_AGiH864
  priority: 102
  providerName: Scholars Portal
Title Effect of FOXP2 transcription factor on immune infiltration of thyroid cancer and its potential clinical value
URI https://search.proquest.com/docview/2723158163
https://pubmed.ncbi.nlm.nih.gov/PMC9531268
https://doaj.org/article/12778d8be1e445de8ba5c26ff79c86fd
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZJIJBLaZuWbJsGFXIqeNfWw5KObegmFLbJoYG9Cb3cumTlZeM99N9n5EeJr7kIY0tInhl7vk8ajRC6BFBOnXAhcyrnGXOkyCwA5YxWTgSnBHioRBRXP8ube_ZjzdcHiI97YbqgfWfreXzYzGP9p4ut3G7cYowTW9ytrhQYDinl4hAdCkqfUfS_PeSllPJ-BRMImFpU9WazBypIyFwBwSjIxAd1qfon-HIaHfnM3Sxfo1cDTsRf-_G8QQchvkXH_cmR_05R7LMO46bCy9v1HcFt8jnjHwD3p-hguEqDigGDHdUPQ4bc1AjUs2tqj11S-g6b6HHdPuJt06boIeh43DGJUzbw8A7dL7__urrJhqMTMscYaTNrSldUUgUHZFmQ3KjccGmCVYDoVJrEMJRRK4tcEW8s96x0AMVsSYJQ3hH6Hh3FJoYzhL0QDqoxI4kF7sgMq7zlLJgAWAzw0wx9GYWpt32GDA3MIkled5LXSfK6l_wMfUvi_l8xJbfubjS733pQsS6IENJLG4rAGPdBWsMdKatKKCfLys_Q51FZGj6GtMJhYmj2j5oIgKtcAsacITHR4qTH6ROwsi6t9mBVH17c8iM6Sa-aoklIfo6O2t0-fALI0tqLjupDeb0uoFwxedEZ7RNrDfOd
link.rule.ids 230,315,733,786,790,870,891,2115,24346,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEYILb8TyNBInpGQTx47tI1SsFuiWHlq0N8uvQKCbrLbZA_x6xnGCGm5wi2JbjvONM9_E488IvQZSXlhufWJlxhJqSZ4YIMpJUVnureTgoUKguDopl-f045qtDxAb98L0SfvW1GlzsUmb-lufW7nd2PmYJzY_XR1JMBxSivk1dB3mK2FXgvTvkfQWRcHiGiaEYHJe1ZvNHoJBQlIJIUZOJl6oF-ufMMxpfuQVh7O4g76MjxrzTH6k-86k9tdfKo7_PJa76PZAQfHbWHwPHfjmProRD6X8-QA1UdAYtxVefF6fEtwFdzZ-XHA8oAfDVRht4zGYaH0xiO-GRoD8rq0dtsGedlg3DtfdJd62XUhMgo7HzZg4CI37h-h88f7saJkMpzIkllLSJUaXNq-E9BbicE4yLTPNhPZGAlmU4f-ILmhhRJ5J4rRhjpYWWJ4piefSWVI8QodN2_jHCDvOLVSjWhADYSnVtHKGUa890DygZjP0ZkRJbaP4hoKgJUCqekhVgFRFSGfoXcDxT8Wgm93faHdf1fDGVU44F04Yn3tKmfPCaGZJWVVcWlFWboZejVagYJ6FxRPd-HZ_qQgHJswE0NcZ4hPzmPQ4LQHQe8XuAeQn_93yJbq5PFsdq-MPJ5-eolth2CFphWTP0GG32_vnwIw686KfB78BpYMS5A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagCNQL5akuUDASJ6S8HCe2j9CyKo-WPVBpxcXyKxDoJqtt9lB-PeM4QRuOvUWJLceZceb74sk3CL0BUJ4bZlxkRFpE1JAs0gCUo7wyzBnBIEJ5onh2Xp5e0E_LYrlT6qtP2je6jpvLVdzUP_vcyvXKJGOeWLI4OxbgOKTkydpWyW10B9YsYTtE_VcAvnmeF2EfE2iYSKp6tdoCISQkFkAzMjKJRL1g_wRlTnMkd4LO_AB9H2835Jr8jredjs2f_5QcbzSfB-j-AEXxu9DkIbrlmkfobihOef0YNUHYGLcVnn9dLgjufFgbXzI4FOrBcORn3DgMrlpfDiK8vhN4wKatLTberzZYNRbX3RVet51PUIKBx58ysRccd0_QxfzDt-PTaKjOEBlKSRdpVZqs4sIZ4OOMpEqkquDKaQGgUfjvJCqnueZZKohVurC0NID2dEkcE9aQ_Cnaa9rGHSJsGTPQjCpONNBTqmhldUGdcgD3AKLN0NvRUnIdRDgkkBdvVtmbVXqzymDWGXrvbfmvodfP7k-0mx9yeOoyI4xxy7XLHKWFdVyrwpCyqpgwvKzsDL0ePUHCevObKKpx7fZKEgaIuOAAY2eITVxkMuL0Chi-V-4eDP3sxj1foXuLk7n88vH883O072ftc1dI-gLtdZutOwKA1OmX_VL4CyIeFWQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+FOXP2+transcription+factor+on+immune+infiltration+of+thyroid+cancer+and+its+potential+clinical+value&rft.jtitle=Frontiers+in+immunology&rft.au=Xu%2C+Lianghui&rft.au=Yang%2C+Zheyu&rft.au=Zhao%2C+Qiwu&rft.au=Feng%2C+Haoran&rft.date=2022-09-20&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.982812&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2022_982812
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon